Schering probe
This article was originally published in The Tan Sheet
Executive Summary
Antitrust division of U.S. Justice Department in February "served a grand jury subpoena on the company seeking documents for the first time" about whether firm's consumer products division entered into an agreement with Wyeth "to lower the commission rate of a consumer products broker," firm says. In March 10 10-K filing with SEC Schering said it is "cooperating with the investigation." Wyeth announced DoJ probe last month (1"The Tan Sheet" Feb. 17, 2003, In Brief)...
You may also be interested in...
Wyeth DoJ probe
Firm "expects to receive a subpoena in the near future" for Department of Justice inquiry "into allegations of collusive practices" with another drug company, Wyeth states in Feb. 11 SEC filing. Case has been referred to a grand jury, Wyeth says. Allegations refer to collusion "relating to commission rates for a sales broker for a small segment of the" firm's OTC business, filing notes, although Wyeth maintains "our practices regarding brokers have not violated the antitrust laws." Schering-Plough disclosed a similar investigation in November. DoJ initiated the inquiry following same-day move by the two firms to reduce fees to Compass Marketing (1"The Tan Sheet" Aug. 19, 2002, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.